Arvinas will present biomarker data from a Phase 1 trial of ARV-102, an orally bioavailable protein degrader designed to cross the blood-brain barrier and eliminate LRRK2, in healthy volunteers and Parkinson's patients. The approach applies targeted protein degradation — removing a disease-associated protein rather than inhibiting it — to a neurodegenerative indication. Results are scheduled for late-breaking presentation at the 2026 International Congress of Parkinson's Disease and Movement Disorders in Seoul.
Key Points
- ARV-102 degrades LRRK2, a protein implicated in Parkinson's pathology
- Oral PROTAC engineered for blood-brain barrier penetration
- Phase 1 biomarker data from healthy volunteers and patients
Longevity Analysis
Targeted protein degradation shifts the therapeutic objective from blocking a malfunctioning protein to clearing it entirely, aligning pharmacology with the cell's own disposal machinery — a principle that underpins much of what keeps neural tissue functional across decades. Biomarker endpoints at this stage matter more than symptom scores, since they indicate whether the intended molecular signal is actually being altered in the brain before clinical effects could be expected. Central nervous system access remains the limiting variable for most degrader programs, making blood-brain barrier penetration the detail worth tracking in these data.
Original published by Longevity.Technology.